Search results
Showing 106 to 120 of 581 results for pregnancy
How you can use our recommendations, tools and resources: maternity and neonatal health
How to use NICE guidance to reduce health inequalities during and after pregnancy.
Evidence-based recommendations on natalizumab originator (Tysabri) and biosimilar (Tyruko) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy in adults.
e-cigarettes and pregnancy: Are nicotine replacement therapy or nicotine-containing e-cigarettes effective to help women stop smoking in...
Evidence-based recommendations on fallopian tube recanalisation by guidewire. This involves injecting dye through a narrow tube inserted into the fallopian tube and if this does not unblock it, using a guidewire.
View recommendations for HTG44Show all sections
Sections for HTG44
This guideline covers care and treatment for adults (aged 18 and over) with type 1 diabetes. It includes advice on diagnosis, education and support, blood glucose management, cardiovascular risk, and identifying and managing long-term complications.
Healthy start vitamins: special report on cost effectiveness (ECD5)
This document describes a special report on the cost effectiveness of moving the Healthy Start vitamin programme from the current targeted offering to a universal offering
involves taking 2 different medicines to end the pregnancy, usually 1 or 2 days apart. The pregnancy is passed through the...
Vitamin D: supplement use in specific population groups (PH56)
This guideline covers vitamin D supplement use. It aims to prevent vitamin D deficiency among specific population groups including infants and children aged under 4, pregnant and breastfeeding women, particularly teenagers and young women, people over 65, people who have low or no exposure to the sun and people with dark skin.
Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes (TA943)
Evidence-based recommendations on hybrid closed loop systems for managing blood glucose levels in type 1 diabetes.
This quality standard covers blood transfusion and reducing the requirements for blood transfusion in adults, young people and children aged 1 year and over. It describes high-quality care in priority areas for improvement. It does not cover use of tranexamic acid for surgery during pregnancy or labour or blood transfusion during pregnancy or labour.
View quality statements for QS138Show all sections
Sections for QS138
How safe are drugs used to treat bipolar disorder in pregnancy and the postnatal period?
Question How safe are drugs used to treat bipolar disorder in pregnancy and the postnatal period? Any explanatory notes(if applicable)
This indicator covers the percentage of adults receiving drug treatment for epilepsy who had a structured review in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM209
Neuropathic pain in adults: pharmacological management in non-specialist settings (CG173)
This guideline covers managing neuropathic pain (nerve pain) with pharmacological treatments (drugs) in adults in non-specialist settings. It aims to improve quality of life for people with conditions such as neuralgia, shingles and diabetic neuropathy by reducing pain and promoting increased participation in all aspects of daily living. The guideline sets out how drug treatments for neuropathic pain differ from traditional pain management.
Contraception: advice for people with bipolar, schizophrenia or other psychoses (IND124)
This indicator covers the percentage of women with schizophrenia, bipolar affective disorder or other psychoses under the age of 45 years who have been given information and advice in the previous 12 months about pregnancy, conception or contraception tailored to their pregnancy and contraceptive intentions. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM78
Neonatal infection: antibiotics for prevention and treatment (NG195)
This guideline covers preventing bacterial infection in healthy babies of up to and including 28 days corrected gestational age, treating pregnant women and pregnant trans men and non-binary people whose unborn baby is at risk of infection, and caring for babies of up to and including 28 days corrected gestational age with a suspected or confirmed bacterial infection. It aims to reduce delays in recognising and treating infection and prevent unnecessary use of antibiotics. The guideline does not cover viral infections.
Show all sections
Sections for NG195
- Overview
- Using this guideline
- Information and support for parents and carers
- Prevention and risk reduction
- Risk factors and clinical indicators: early-onset neonatal infection
- Risk factors and clinical indicators: late-onset neonatal infection
- Investigations before starting antibiotics for early-onset or late-onset neonatal infection
- Principles around use of antibiotics for early-onset or late-onset neonatal infection